Colombia Point of Care Diagnostics Market Overview, 2031

Key Insights

• According to the research report, "Colombia Point of Care Diagnostics Market Outlook, 2031," published by Bonafide Research, the Colombia Point of Care Diagnostics Market is anticipated to add to more than 75.4 Million by 2026-31.
• Colombia’s Point-of-Care (POC) diagnostics adoption is heavily driven by its General System of Social Security in Health (Sistema General de Seguridad Social en Salud - SGSSS). To bridge acute healthcare access gaps between major urban metropolitan hubs (like Bogotá, Medellín, and Cali) and remote, underserved departments (such as Chocó, Amazonas, and La Guajira), health maintenance organizations (EPS - Entidades Promotoras de Salud) and care providers (IPS - Instituciones Prestadoras de Salud) are deploying portable diagnostic platforms into primary care health posts.
• Colombia's diverse topographies and tropical climates make vector-borne arboviruses specifically Dengue, Zika, Chikungunya, and Malaria ongoing public health priorities. Traditional diagnostic pathways relying on central reference laboratories often generated turnaround delays during peak seasonal outbreaks. A key breakthrough in Colombian field surveillance is the integration of portable isothermal nucleic acid amplification (LAMP) devices and microfluidic rapid antigen test cartridges. These low-cost, portable platforms allow municipal health units and rural mobile health teams to run differential molecular evaluations from a single blood or serum sample in under 30 minutes, enabling rapid clinical triage and immediate vector-control responses in high-transmission zones.
• Point-of-care testing in Colombia is transitioning from standalone test strips into digitally integrated, cloud-connected diagnostic nodes. Under national digital health transformation strategies overseen by the Ministry of Health and Social Protection (Ministerio de Salud y Protección Social), modern POCT instruments deployed across emergency rooms, primary health clinics, and home care services feature automated cellular and Bluetooth connectivity.

Market Outlook

• As health authorities focus on mitigating the rising burden of non-communicable cardiometabolic conditions (such as Type 2 diabetes and hypertension), public and private health network budgets are prioritizing decentralized screening tools. The systematic expansion of multi-parametric benchtop analyzers in outpatient health centers (IPS) and retail pharmacy networks allows general practitioners to monitor HbA1c, lipid profiles, and renal parameters on site, preventing costly tertiary hospital readmissions.
• Driven by rising public health awareness and the growth of telemedicine services, Colombian consumers are increasingly adopting connected self-monitoring devices for continuous glucose tracking, pregnancy, and respiratory pathogen screening. This dual-track model combining primary care health post upgrades in remote departments with a booming retail self-testing market in urban centers positions Colombia as a central growth hub for point-of-care technology developers in the Andean region.
• Major international commercial suppliers serving the Colombian point-of-care ecosystem include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Danaher Corporation (Cepheid), Siemens Healthineers, bioMérieux, Becton, Dickinson and Company (BD), and Mindray Medical, operating under sanitary registration and medical device clearance frameworks enforced by INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) and guided by public health directives from the Ministerio de Salud y Protección Social and the Instituto Nacional de Salud (INS).

Market Dynamics

Driver: Expansion of decentralized health services and universal coverage initiatives
Colombia’s healthcare framework anchored by strong structural reforms aimed at universal health coverage is shifting focus toward primary and preventive care models. Regional healthcare providers and decentralized clinics are increasingly deploying point-of-care (POC) diagnostics to streamline clinical pathways, accelerate triage, and reduce heavy patient congestion in major metropolitan hospitals.
Challenge: Rigid administrative processes and lengthy review timelines
Commercializing diagnostic technologies requires navigating detailed regulatory procedures governed by national health authorities. Because comprehensive technical evaluations are standard, administrative review queues can introduce considerable time-to-market delays and high compliance documentation costs for foreign manufacturers.
Trend: Integration of connected digital diagnostics and point-of-care data sharing
There is an accelerated technological transition toward cloud-connected diagnostic tools and microfluidic platforms. These devices allow decentralized screening data from rural clinics or urban pharmacies to integrate seamlessly with electronic health records, empowering real-time disease tracking and efficient resource deployment.

Segment Analysis

Colombia Point of Care Diagnostics By Product
• Glucose monitoring kits in Colombia are increasingly evolving from conventional meter-and-strip products toward connected diabetes-management tools that can store readings, communicate with smartphones, and support longitudinal monitoring. Product differentiation is therefore shifting toward smaller sample requirements, easier strip handling, automated result capture, and interfaces suitable for repeated self-testing. Colombia's INVIMA framework places self-diagnosis and self-control IVDs within its regulated diagnostic category, while the broader IVD system uses risk-based classification and registration requirements. This makes intended use, user instructions, analytical reliability, and traceability important elements of glucose-monitoring product design.
• Infectious-disease POC kits in Colombia span rapid antigen and antibody formats as well as molecular systems that bring pathogen detection closer to the patient. Their distinctive role is to shorten the diagnostic workflow where immediate information can influence treatment, isolation, referral, or further laboratory testing. INVIMA classifies IVDs according to sanitary risk, with microbiology and molecular-biology products specifically represented within its classification framework. Colombia also actively monitors rapid-test commercialization, including digital-channel sales, emphasizing the importance of sanitary registration and differentiation between professional-use and self-diagnostic products.
• Pregnancy and fertility kits are naturally suited to decentralized use because urine-based testing can be performed privately without an initial laboratory appointment. The category extends from conventional pregnancy strips to ovulation and fertility-window tests, with newer products increasingly using digital readers or smartphone-supported interpretation. Colombia's regulatory framework explicitly includes self-diagnosis and self-control tests within Category II IVDs, making consumer usability an important consideration alongside analytical performance.
• Hematology POC kits bring selected blood measurements closer to the clinical encounter through portable analyzers, cartridges, and simplified specimen workflows. Applications can include hemoglobin, coagulation-related parameters, and other blood measurements that complement centralized laboratory testing. Colombia's IVD classification specifically recognizes hematology and coagulation within its regulated diagnostic categories, while INVIMA's authorization framework evaluates the technical capacity of manufacturers, manufacturing processes, product quality, safety, and functionality.
• Cardiometabolic monitoring kits in Colombia increasingly combine glucose, cholesterol, coagulation, and related measurements with digital disease-management workflows. The distinctive product direction is toward connected devices that transform individual readings into longitudinal records rather than leaving results isolated on a meter. Colombia's IVD framework covers areas such as blood chemistry, coagulation, and self-diagnosis, while INVIMA's newer semantic-standard and UDI-DI requirements strengthen product identification and traceability across commercialization and distribution.
• Urinalysis kits are particularly suited to decentralized testing because urine collection is non-invasive and multi-parameter strips can provide preliminary information with minimal equipment. The segment includes traditional visually interpreted dipsticks as well as reader-assisted systems that standardize interpretation and digitally capture results. INVIMA specifically includes uroanalysis within Category II IVDs, placing these products within a defined regulatory framework while allowing them to serve as an accessible screening layer before more comprehensive laboratory investigation.
• Cholesterol test strips connect conventional lipid testing with near-patient cardiometabolic screening through small-sample testing and compact readers. Product development increasingly emphasizes simplified capillary collection, rapid processing, automated interpretation, and digital recording rather than the disposable strip alone. Because blood chemistry is explicitly included within Colombia's regulated IVD categories, cholesterol products operate within a structured regulatory environment.
• Other Products encompass cardiac biomarkers, inflammatory markers, electrolytes, blood gases, coagulation assays, toxicology, reproductive biomarkers, and multi-analyte platforms. Their distinctive development path is toward compact analyzers and cartridge architectures capable of combining several laboratory functions while minimizing manual preparation. Colombia's IVD classification explicitly covers areas including endocrinology, toxicology, immunology, coagulation, blood gases, and other diagnostic fields, creating a broad regulatory base for diversified POC platforms.



Colombia Point of Care Diagnostics By Technology/Platform
• Lateral flow assays remain well suited to Colombia's decentralized diagnostics environment because they combine portability, rapid operation, and limited equipment requirements. They support applications ranging from pregnancy and fertility testing to infectious-disease screening and other rapid assays. A distinctive Colombian consideration is the regulatory distinction surrounding self-diagnosis: INVIMA identifies self-diagnosis and self-control products within its IVD classification, while the agency has also warned against the commercialization of rapid tests without appropriate sanitary registration.
• PCR and isothermal nucleic-acid amplification platforms bring molecular pathogen detection closer to the point of care through compact analyzers and integrated cartridges. These systems can combine sample preparation, amplification, and detection in a controlled workflow, reducing dependence on conventional laboratory infrastructure. Colombia's regulatory framework specifically recognizes molecular biology within its IVD classification, while higher-risk products receive corresponding regulatory scrutiny.
• Microfluidics and immunoassays compress laboratory processes into cartridges and portable instruments. Microfluidic systems can manage small sample volumes while integrating preparation, reaction, separation, and detection, whereas immunoassays support biomarkers such as hormones, proteins, antigens, and antibodies. In Colombia, these technologies align with the broader movement toward decentralized testing because they can reduce manual laboratory steps and support multi-analyte platforms.
• Dipsticks and test strips remain among the most accessible POC formats in Colombia because they require little instrumentation and can be used directly at the testing site. Applications include urinalysis, glucose monitoring, pregnancy testing, fertility testing, and selected cardiometabolic assessments. Reader-assisted versions increasingly add automated interpretation and digital result capture, transforming basic strips into more standardized diagnostic workflows.

Colombia Point of Care Diagnostics By End-User
• Colombian hospitals and critical-care centers can use POC diagnostics when rapid measurements complement centralized laboratory testing during acute clinical situations. Emergency departments, intensive-care units, operating environments, and other high-dependency areas can benefit from testing performed close to the patient, reducing reliance on specimen transport and conventional laboratory turnaround. INVIMA's regulatory system treats IVDs as regulated products requiring appropriate authorization and emphasizes safety, performance, quality, and post-market surveillance.
• Clinical and diagnostic laboratories provide an important quality-management backbone for Colombia's decentralized diagnostic environment. Their role can include method verification, quality control, calibration, operator training, troubleshooting, review of unusual results, and confirmation testing when necessary. POC therefore complements rather than necessarily replaces centralized laboratory capabilities.
• Home care and self-testing represent the consumer-facing side of Colombia's POC diagnostics ecosystem, particularly for glucose, pregnancy, fertility, selected infectious-disease, and other monitoring applications. INVIMA explicitly includes self-diagnosis and self-control products in its IVD classification, while its surveillance activities emphasize the need to distinguish authorized self-tests from professional-use rapid tests. The agency has also warned consumers about rapid diagnostic tests sold through digital platforms without sanitary registration.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Point of Care Diagnostics Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product
• Glucose Monitoring Kits
• Infectious Diseases Testing Kits
• Pregnancy And Fertility Testing Kits
• Hematology Testing Kits
• Cardiometabolic Monitoring Kits
• Urinalysis Testing Kits
• Cholesterol Test Strips
• Other Products

By Technology/Platform
• Lateral Flow Assays
• Molecular Diagnostics (PCR/INAAT)
• Microfluidics & Immunoassays
• Dipsticks & Test Strips

By End-User
• Hospitals & Critical Care Centers
• Clinical & Diagnostic Laboratories
• Home Care & Self-Testing

By Mode Of Purchase
• Prescription Based Products
• OTC Products

By Sample
• Blood
• Urine
• Nasal and Oropharyngeal Swabs